The bill creates a targeted precision oncology program that should improve diagnosis, care coordination, and trial access for veterans with prostate cancer, but its limited three‑year funding, concentration at 27 centers, and administrative/reporting burdens risk leaving many veterans without sustained or equitable access.
Veterans diagnosed with prostate cancer gain access to a VA Precision Oncology Program offering genetic sequencing, biomarker-driven trials, and specialized care at designated centers.
Veterans treated at designated centers receive more coordinated, expert care because centers must staff multidisciplinary specialists and at least two full‑time research staff, improving clinical decision-making and research enrollment.
Veterans in remote or rural areas gain better access to expert consultation and trials through telemedicine tumor boards and travel support.
All veterans and participating centers face sustainability risk because authorized funding is limited to $15.5M annually for three years, so continued operations or scale-up may lack funding after FY2029.
Veterans who do not live near a designated center—particularly those served by smaller VA facilities—may continue to face care and trial access gaps if affiliated sites lack capacity.
Concentrating program resources at 27 specific VA centers risks geographic inequities, leaving many veterans served primarily at smaller facilities with fewer benefits from the program.
Based on analysis of 2 sections of legislative text.
Creates a VA precision oncology program for prostate cancer, designates centers of excellence, requires staffing and reporting, and authorizes $15.5M/year for FY2027–FY2029.
Official title: Direct the Secretary of Veterans Affairs to establish a precision oncology program for cancer of the prostate at the Department of Veterans Affairs, and for other purposes.
Introduced July 15, 2026 by Jerry Moran · Last progress July 15, 2026
Creates a Veterans Affairs Precision Oncology Program focused on prostate cancer that designates at least 21 VA medical centers as centers of excellence to provide specialized clinical care, genomic sequencing, registries, clinical trials access, telemedicine, biopsy support, travel assistance, mentoring, and research staffing. It establishes a program leadership team based at the Seattle VA Medical Center, requires implementation and annual reporting to Congress, mandates rolling performance reviews, and authorizes $15.5 million per year for FY2027–FY2029 to run the program. The law lists 27 provisional centers that become effective on enactment, sets minimum staffing and activity requirements for each center, allows the Secretary to add or terminate centers (with notice to congressional committees after 2030), and requires an implementation plan within 180 days and a comprehensive plan by 2029.